LIQUID BIOPSY OF CFDNA REVEALS ATP7B VARIANTS AS NOVEL BIOMARKERS OF LIVER METASTASIS IN HIGH-GRADE SEROUS OVARIAN CANCER2
Anais do Congresso Brasileiro de Cancerologia · 2025 · 33 (73) · 22-22
DOI: 10.29327/2702205.33.73-17 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anais do Congresso Brasileiro de Cancerologia, 2025. Verfasst von FELIPE und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
High-grade serous ovarian carcinoma (HGSOC) is a highly lethal disease and the most clinically relevant subtype among epithelial ovarian tumors. A key event associated with its aggressiveness is its metastatic potential, whereby tumor cells disseminate from the primary site. Approximately 75% of HGSOC cases are diagnosed at advanced stages, and genetic factors are often associated. Sometimes, genetic variants promoting the migration and establishment of cancer cells at secondary sites may be frequent. The identification of such variants represents a promising strategy to improve the understanding of the disease
Zitieren
APA
FELIPE, O, A. S., SALES, O, P. G. D., BRAGA, & C, L. D. (2025). LIQUID BIOPSY OF CFDNA REVEALS ATP7B VARIANTS AS NOVEL BIOMARKERS OF LIVER METASTASIS IN HIGH-GRADE SEROUS OVARIAN CANCER2. Anais do Congresso Brasileiro de Cancerologia, 33(73), 22-22. https://doi.org/10.29327/2702205.33.73-17
Vancouver
FELIPE, O AS, SALES, O PGD, BRAGA, C LD. LIQUID BIOPSY OF CFDNA REVEALS ATP7B VARIANTS AS NOVEL BIOMARKERS OF LIVER METASTASIS IN HIGH-GRADE SEROUS OVARIAN CANCER2. Anais do Congresso Brasileiro de Cancerologia. 2025;33(73):22-22. doi:10.29327/2702205.33.73-17
BibTeX
@article{FELIPE2025,
author = {FELIPE and O, A S and SALES and O, P G D and BRAGA and C, L D},
title = {LIQUID BIOPSY OF CFDNA REVEALS ATP7B VARIANTS AS NOVEL BIOMARKERS OF LIVER METASTASIS IN HIGH-GRADE SEROUS OVARIAN CANCER2},
journal = {Anais do Congresso Brasileiro de Cancerologia},
year = {2025},
volume = {33},
number = {73},
pages = {22--22},
doi = {10.29327/2702205.33.73-17}
}
EUVIMED